bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, today announced that Michael...
bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will present at the Cleveland...
bioAffinity Technologies , Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage cancer, will ring the Nasdaq Stock...
bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported...
bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced the publication of a paper titled “Porphyrin-modified beads for use as compensation controls in flow cytometry” in the peer-reviewed...
bioAffinity Technologies , Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close....
bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced its commercialization team, including the addition of Julie Anne Overton, a veteran of print and broadcast journalism, corporate communications...
bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) today announced publication of “ Detection of early-stage lung cancer in sputum using automated flow cytometry and machine learning ” detailing...
bioAffinity Technologies, Inc . (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “ Porphyrin...
/PRNewswire/ -- Argus Research, an independent investment research firm, has launched Equity Research Report coverage on bioAffinity Technologies, Inc....